Institutional members access full text with Ovid®

Share this article on:

Safety of Thiopurine Therapy in Inflammatory Bowel Disease: Long-term Follow-up Study of 3931 Patients

Chaparro, María MD, PhD1,2; Ordás, Ingrid MD3,2; Cabré, Eduard MD, PhD4,2; Garcia-Sanchez, Valle MD, PhD5; Bastida, Guillermo MD6,2; Peñalva, Mireia MD7; Gomollón, Fernando MD, PhD8,2; García-Planella, Esther MD9; Merino, Olga MD10; Gutiérrez, Ana MD11; Esteve, Maria MD, PhD12; Márquez, Lucia MD13; Garcia-Sepulcre, Maria MD14; Hinojosa, Joaquín MD, PhD15; Vera, Isabel MD, PhD16; Muñoz, Fernando MD17; Mendoza, Juan L. MD, PhD18; Cabriada, Jose L. MD19; Montoro, Miguel A. MD, PhD20; Barreiro-de Acosta, Manuel MD, PhD21; Ceña, G. MD22; Saro, Cristina MD23; Aldeguer, Xavier MD24; Barrio, Jesús MD25; Maté, José MD, PhD1,2; Gisbert, Javier P. MD, PhD1,2

doi: 10.1097/MIB.0b013e318281f28f
Original Clinical Article

Background: To evaluate the safety of thiopurines in patients with inflammatory bowel disease. To identify predictive factors associated with the development of thiopurine-induced adverse events.

Methods: Long-term incidence of adverse events was estimated in patients from a prospectively maintained Spanish nationwide database using Kaplan–Meier analysis. Cox regression analysis was performed to identify potential predictive factors of adverse events.

Results: Three thousand nine hundred and thirty-one patients were included. Ninety-five percent of patients were on azathioprine. The median follow-up with thiopurines was 44 months (range, 0–420). Adverse events occurred at a median of 1 month after starting treatment. The cumulative incidence of adverse events was 26%, with an annual risk of 7% per patient-year of treatment. Most frequent adverse events were nausea (8%), hepatotoxicity (4%), myelotoxicity (4%), and pancreatitis (4%). Four patients had lymphoma. Female and Crohn's disease increased the risk of having nausea. The risk of hepatotoxicity was lower in females and higher in Crohn's disease. The risk of myelotoxicity was significantly higher in patients treated with mercaptopurine and in females. The risk of pancreatitis was higher in Crohn's disease. Overall, 17% of patients discontinued thiopurine treatment due to adverse events. Thirty-seven percent of these patients started thiopurines again and 40% of them had adverse events again.

Conclusions: As many as 1 of 4 patients on thiopurine therapy had adverse events during follow-up. A relatively high proportion of patients (17%) had to discontinue the treatment with thiopurines due to adverse events. However, more than half of patients that restarted thiopurine treatment after its discontinuation due to adverse events tolerated it. Several predictive factors for some adverse events have been identified.

Article first published online 9 May 2013

1Gastroenterology Unit, La Princesa and Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain;

2Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain;

3Gastroenterology Unit, Clínic, Barcelona, Spain;

4Germans Trias i Pujol, Badalona, Spain;

5Reina Sofía, Córdoba, Spain;

6La Fe, Valencia, Spain;

7Bellvitge, Barcelona, Spain;

8Lozano Blesa, Zaragoza, Spain;

9Santa Creu i Sant Pau, Barcelona, Spain;

10Cruces, Vizcaya, Spain;

11Alicante, Alicante, Spain;

12Mutua Terrassa, Terrassa, Spain;

13del Mar, Barcelona, Spain;

14Elche, Elche, Spain;

15Manises, Valencia, Spain;

16Puerta de Hierro, Madrid, Spain;

17León, León, Spain;

18Clínico San Carlos, Madrid, Spain;

19Galdakao, Vizcaya, Spain;

20San Jorge, Huesca, Spain;

21Clínico de Santiago, Santiago de Compostela, Spain;

22Royo Villanova, Zaragoza, Spain;

23Cabueñes, Gijón, Spain;

24Doctor Josep Trueta, Girona, Spain; and

25Río Hortega, Valladolid, Spain.

Reprints: María Chaparro, MD, PhD, Americio, 17 portal E 2°C, 28021 Madrid, Spain (e-mail: mariachs2005@gmail.com).

The authors have no conflicts of interest to disclose.

Received September 21, 2012

Accepted October 02, 2012

© Crohn's & Colitis Foundation of America, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website